P R Walker

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
    P R Walker
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Immunol 158:4521-4. 1997
  2. ncbi request reprint The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells
    P R Walker
    Laboratory of Tumor Immunology, Division of Oncology, and Department of Neurosurgery, University Hospital Geneva, Geneva, Switzerland
    J Immunol 165:3128-35. 2000
  3. pmc Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
    P Saas
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Clin Invest 99:1173-8. 1997
  4. ncbi request reprint Tumor expression of Fas ligand (CD95L) and the consequences
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 Rue Micheli du Crest, CH 1211, Geneva 14, Switzerland
    Curr Opin Immunol 10:564-72. 1998
  5. ncbi request reprint Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, CH 1211 Geneva 14, Switzerland
    Cell Immunol 206:51-8. 2000

Collaborators

  • P Saas
  • J Tschopp
  • M Hahne
  • E G Van Meir
  • N de Tribolet
  • L French
  • G Perrin
  • P Y Dietrich
  • A L Quiquerez
  • V Schnuriger

Detail Information

Publications5

  1. ncbi request reprint Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
    P R Walker
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Immunol 158:4521-4. 1997
    ..The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies...
  2. ncbi request reprint The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells
    P R Walker
    Laboratory of Tumor Immunology, Division of Oncology, and Department of Neurosurgery, University Hospital Geneva, Geneva, Switzerland
    J Immunol 165:3128-35. 2000
    ..This observation correlated with potent ex vivo cytotoxicity of brain-infiltrating CTLs, specific for the immunodominant epitope CW3170-179 expressed on P815-CW3 tumor cells...
  3. pmc Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
    P Saas
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Clin Invest 99:1173-8. 1997
    ..Overall, our findings suggest that FasL-induced apoptosis by astrocytoma cells may play a significant role in both immunosuppression and the regulation of tumor growth within the central nervous system...
  4. ncbi request reprint Tumor expression of Fas ligand (CD95L) and the consequences
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 Rue Micheli du Crest, CH 1211, Geneva 14, Switzerland
    Curr Opin Immunol 10:564-72. 1998
    ..The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment...
  5. ncbi request reprint Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, CH 1211 Geneva 14, Switzerland
    Cell Immunol 206:51-8. 2000
    ..Understanding how Fas may be differentially regulated in vivo and in vitro is an important issue for the optimal manipulation of T cells for adoptive immunotherapy protocols...